[{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altesa Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Altesa Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Drug Innovation Ventures at Emory","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"ALT-2023","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altesa Biosciences \/ Drug Innovation Ventures at Emory","highestDevelopmentStatusID":"5","companyTruncated":"Altesa Biosciences \/ Drug Innovation Ventures at Emory"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vapendavir","moa":"Capsid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altesa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Altesa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vapendavir","moa":"Capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altesa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altesa Biosciences \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Altesa Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : Vapendavir is a broad-spectrum antiviral medicine that prevents the virus from entering human cells and reproducing. It is being studied for rhinovirus infections in people with COPD.

                          Product Name : BTA798

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 19, 2025

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : The collaboration includes a license to ALT-2023, a broadly active nucleoside analogue that is late stage preclinical development, as well as options to additional compounds addressing RNA viruses.

                          Product Name : ALT-2023

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 02, 2022

                          Lead Product(s) : ALT-2023

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Drug Innovation Ventures at Emory

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : BTA798 (Vapendavir) has shown promising preclinical and clinical data demonstrating effective control of certain respiratory viruses, can potentially be used to treat epidemic hand, foot and mouth disease (HFMD) and HRV infection in COPD Patients.

                          Product Name : BTA798

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 26, 2022

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : With the newly announced AViDD award, Altesa options include relevant compounds advanced by DRIVE stemming from Emory’s Antiviral Countermeasure Development Center.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 25, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : National Institutes of Health

                          Deal Size : $52.0 million

                          Deal Type : Funding

                          blank